Skip to main content

Table 3 The network meta-analysis results (presented as odds ratio) for all-cause mortality

From: Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis

ABLC

AmB

Caspofungin

Fluconazole

Itraconazole

L-AmBa

L-AmBb

Micafungin

NAT

Voriconazole

2.13 (0.25, 15.53)

         

4.00 (0.36, 30.31)

2.00 (0.29, 9.16)

        

0.82 (0.03, 13.01)

0.44 (0.04, 3.16)

0.24 (0.01, 2.79)

       

2.23 (0.19, 18.54)

1.06 (0.32, 2.75)

0.55 (0.08, 4.32)

2.38 (0.27, 32.66)

      

2.30 (0.13, 30.41)

1.00 (0.13, 8.32)

0.53 (0.05, 6.77)

2.51 (0.14, 58.87)

0.97 (0.10, 10.44)

     

2.92 (0.51, 17.19)

1.44 (0.43, 4.65)

0.72 (0.24, 3.10)

3.17 (0.38, 54.22)

1.34 (0.31, 7.65)

1.45 (0.18, 10.99)

    

2.28 (0.10, 27.64)

1.10 (0.11, 5.97)

0.53 (0.04, 5.76)

2.53 (0.16, 43.72)

1.03 (0.17, 4.87)

1.14 (0.05, 15.78)

0.72 (0.07, 5.08)

   

1.57 (0.13, 26.34)

0.79 (0.18, 4.60)

0.41 (0.05, 5.77)

1.93 (0.13, 34.81)

0.74 (0.15, 6.87)

0.73 (0.06, 12.62)

0.55 (0.09, 4.65)

0.69 (0.09, 14.59)

  

2.49 (0.29, 24.91)

1.12 (0.23, 8.07)

0.58 (0.12, 6.07)

2.68 (0.24, 74.04)

1.08 (0.20, 11.04)

1.16 (0.12, 15.57)

0.78 (0.22, 4.00)

1.03 (0.14, 18.98)

1.49 (0.13, 15.91)

 
  1. ABLC Amphotericin B lipid complex, AmB Conventional amphotericin B, L-AmB Liposomal amphotericin B, NAT No antifungal treatment
  2. a1 mg/kg/day; b3 mg/kg/day